Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2020-001965Source: DataRank Database

High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer is a research paper published in Journal for ImmunoTherapy of Cancer (2021). On theSindex it has a DataRank of 0. It has been cited 37 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access37 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Impact (FWCI 4.13)OA: goldTopics (45)Linked Datasets (10)DataCite Reuse (10)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Sandra Pommey ORCID,Mayra Carneiro ORCID,Laurence Buisseret ORCID,Isabelle Cousineau ORCID,Paméla Thébault

Live enrichment

PubMed:33771891 OpenAlex:https://openalex.org/W3139360595

FWCI

4.13

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by-nc

journalhttps://jitc.bmj.com/content/jitc/9/3/e001965.full.pdf

publisherhttps://jitc.bmj.com/content/jitc/9/3/e001965.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1136/jitc-2020-001965

journalhttps://doi.org/10.1136/jitc-2020-001965

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33771891

Fields of Study

Adenosine and Purinergic SignalingPhagocytosis and Immune RegulationNuclear Receptors and Signaling

MeSH Terms

RNA-SeqAdenosineAdenosine TriphosphateAnimalsAntineoplastic AgentsApyraseFemaleHumansHydrolysisMiddle AgedOvarian NeoplasmsBiomarkers, TumorSignal TransductionAntigens, CD5'-NucleotidaseNeoplasms, Cystic, Mucinous, and SerousMice, KnockoutGene Expression ProfilingXenograft Model Antitumor AssaysDatabases, GeneticCell Line, TumorMiceGPI-Linked ProteinsSingle-Cell AnalysisTranscriptomeNeoplasm Grading

Keywords

Immune systemOvarian cancerCancer researchGene signatureTranscriptomeTumor microenvironmentCancerCD8BiologyMedicineMicroarrayMicroarray analysis techniquesImmunologyGene expressionInternal medicineGene

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma

10.6084/m9.figshare.22619522.v1figshare

Additional file 1 of Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma

10.6084/m9.figshare.22619522figshare

Additional file 2 of Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma

10.6084/m9.figshare.22619525.v1figshare

Additional file 3 of Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma

10.6084/m9.figshare.22619528.v1figshare

Additional file 3 of Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma

10.6084/m9.figshare.22619528figshare

Additional file 5 of Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma

10.6084/m9.figshare.22619534.v1figshare

Additional file 2 of Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma

10.6084/m9.figshare.22619525figshare

Additional file 4 of Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma

10.6084/m9.figshare.22619531figshare

Additional file 5 of Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma

10.6084/m9.figshare.22619534figshare

Additional file 4 of Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma

10.6084/m9.figshare.22619531.v1figshare